FUNDAMENTALS
EdgeFII/DII
LAURUSLABSLaurus Labs
₹2,294.60-0.49%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
LAURUSLABSNSE · EquityPharmaceuticals

Laurus Labs

ISIN
INE947Q01028
Instrument key
NSE_EQ|INE947Q01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,294.60-11.40 · -0.49%
Day rangecircuit ₹2,065.20 – ₹2,524.00
2,286.80
2,320.00

as of 21/11/2026, 6:20:37 pm

Open
₹2,294.10
Day high
₹2,320.00
Day low
₹2,286.80
Prev. close
₹2,306.00
Volume
8.79 L
VWAP
₹2,303.73

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

Max · monthly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · MAX
+2286.48%
96.15 → 2,294.60
Period high
₹2,488.00
1/11/2026
Period low
₹59.00
1/3/2020
From high
-7.77%
+3789.15% from low
Avg volume
4.53 Cr
543.61 Cr total
Volatility · ann.
46.8%
120 candles · 59 up / 61 down
1 Nov 2026O 2,406.00H 2,488.00L 2,190.00C 2,294.60Vol 4.19 Cr
SMA 20SMA 50Averages need 50 candles before they begin
Candle data120 rows of open, high, low, close and volumeShowHide
1 Nov 20262,406.002,488.002,190.002,294.60-4.63%298.004.19 Cr
1 Oct 20261,973.602,405.501,933.502,405.50+21.88%472.003.94 Cr
1 Sept 20261,888.902,055.301,811.701,980.00+4.82%243.603.82 Cr
1 Aug 20261,821.001,949.001,769.401,915.00+5.16%179.607.02 Cr
1 Jul 20261,525.001,826.601,448.201,816.20+19.10%378.405.34 Cr
1 Jun 20261,372.401,531.201,342.901,517.40+10.57%188.305.28 Cr
1 May 20261,102.201,393.401,102.001,362.00+23.57%291.404.73 Cr
1 Apr 20261,020.101,144.85994.251,100.95+7.93%150.603.44 Cr
1 Mar 20261,030.001,073.90936.30992.70-3.62%137.603.59 Cr
1 Feb 2026970.001,103.55917.951,075.80+10.91%185.602.97 Cr

Historical price and volume data · Showing 1–10 of 120

1 / 12

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

93.07
Company
93.07
Sector
-45.69

Worse than sector by 304%

P/B

Price ÷ book value per share

20.46
Company
20.46
Sector
4.2

Worse than sector by 387%

ROA

Net income ÷ total assets

11.58%
Company
11.58%
Sector
1.19%

Better than sector by 873%

ROE

Net income ÷ shareholders' equity

22.11%
Company
22.11%
Sector
-0.4%

Better than sector by 5627%

ROCE

EBIT ÷ capital employed

20.91%
Company
20.91%
Sector
15.44%

Better than sector by 35%

Quick Ratio

Liquid assets ÷ current liabilities

0.68
Company
0.68
Sector
4.78

Worse than sector by 86%

EV/EBITDA

Enterprise value ÷ EBITDA

52.54
Company
52.54
Sector
22.9

Worse than sector by 129%

04/Business

About the company

Sector: Pharmaceuticals

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.

Sector market cap (INR)
₹1,24,002 Cr

reported in crore

Sector market cap (USD)
$13.78B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹2,219 Cr
+9.03% vs Jun 2026
Net profit · Sep 2026
₹437 Cr
+20.65% vs Jun 2026
Operating margin
26.7%
was 23.6%
Revenue CAGR · 4p
7.5%
profit 19.9% · op 21.9%
Filed order
Revenue2,2192,0351,8231,784
Revenue growthreported9.0%11.6%2.2%—
Operating profit592481361327
Operating profit growthreported22.9%33.2%10.7%—
Operating marginderived26.7%23.6%19.8%18.3%
Net profit437362282253
Net profit growthreported20.6%28.4%11.4%—
Net marginderived19.7%17.8%15.5%14.2%
EPS — basic₹/share, annual——16.47—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue6,8135,5545,0416,041
Other Income5575266
Total Revenue6,8685,6295,0676,047
Total Expenses5,6865,1454,8314,938
Profit Before Tax1,1824842361,109
Tax29213068312
Profit After Tax890354168797
EPS - Basic16.476.652.9814.69
EPS - Diluted16.456.642.9714.64

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹10,511 Cr
+12.59% YoY
Total liabilities
₹5,080 Cr
Net worth
₹5,431 Cr
Liabilities ÷ assets
48.3%
lower means a lighter balance sheet
Filed order
Total assets10,5119,3368,3877,660
Total liabilities5,0804,7334,2713,612
Net worthderived5,4314,6034,1164,049
Liabilities ÷ assetsderived48.3%50.7%50.9%47.1%
Asset growthderived12.6%11.3%9.5%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets5,6825,0034,5524,199
Current Assets4,8294,3323,8353,462
Total Assets10,5119,3368,3877,660
Current Liabilities3,6353,5403,1122,432
Net Current Asset1,1947937231,029
Non-Current Liabilities1,4441,1931,1591,179
Equity Capital5,4314,6034,1164,049
Total Equity & Liabilities10,5119,3368,3877,660

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹1,624 Cr
+169.84% YoY
Investing
-₹1,089 Cr
Financing
-₹525 Cr
Free cash flow
₹535 Cr
operating + investing
Filed order
Operating activities1,624602666994
Operating changereported169.8%-9.6%-33.0%—
Investing activities-1,089-682-822-996
Investing changereported-59.7%17.1%17.4%—
Financing activities-52539250-27
Financing changereported-1435.8%-84.3%1037.8%—
Net cash flowderived10-4193-29
Free cash flowoperating + investing535-80-157-2

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax1,1824842361,109
Income before WC changes1,8921,1147991,595
Change in Assets-562-543-275-136
Change in Liabilities587168246-179
Change in WC25-375-29-315
Cash flow from Operations1,624602666994
Cash flow from Investing-1,089-682-822-996
Cash flow from Financing-52539250-27
Total Cash Flow10-4193-29
Cash (Start of the year)1001394675
Cash (End of the year)11310013946

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
27.47%
0.00 pts QoQ
FII
30.84%
+2.84 pts QoQ
DII (other)
3.60%
+0.01 pts QoQ
Mutual funds
8.26%
-1.89 pts QoQ
Retail & others
29.83%
-0.95 pts QoQ
Filed order
Promoters27.5%27.5%27.5%27.5%
FII30.8%28.0%25.8%26.5%
DII (other)3.6%3.6%2.7%2.9%
Mutual funds8.3%10.2%11.2%9.5%
Retail & others29.8%30.8%32.7%33.6%
Promoters — QoQ changepts, derived0.0%-0.0%0.0%—
FII — QoQ changepts, derived2.8%2.2%-0.7%—
DII (other) — QoQ changepts, derived0.0%0.8%-0.2%—
Mutual funds — QoQ changepts, derived-1.9%-1.1%1.7%—
Retail & others — QoQ changepts, derived-1.0%-1.9%-0.9%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendInterim₹1.0050.0%06 Nov 202606 Nov 202629 Oct 2026
DividendInterim₹1.2060.0%08 May 202608 May 202630 Apr 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Beyond the big names: 6 NIFTY 500 stocks that quietly rallied up to 200% in six months
    3d ago18/11/2026, 3:51:22 pm
    Beyond the big names: 6 NIFTY 500 stocks that quietly rallied up to 200% in six months

    Cupid, Ather Energy, and Laurus Labs are among the top six stocks which have quietly rallied up to the tune of 200% in the last six months despite market volatility. Here's what investors need to know.

Showing 1–1 of 1 article